Kai-Hsiang Shu

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Urinary π-glutathione S-transferase Predicts Advanced Acute Kidney Injury Following Cardiovascular Surgery

Kai-Hsiang Shu, Chih‐Hsien Wang, Che‐Hsiung Wu et al. · Scientific Reports · 2016 · 56 citations · Full text

Urology, Renal Disease, Renal Function +12

Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients

Yen‐Ling Chiu, Wei‐Chou Lin, Kai-Hsiang Shu et al. · Frontiers in Immunology · 2021 · 42 citations · Full text

Glomerulonephritis in ankylosing spondylitis.

Kai-Hsiang Shu, J.‐D. Lian, Yanrong Yang et al. · PubMed · 1986 · 30 citations

Glomerular Disease, Vasculitis, Immunology +21